Metabolic Disorder in Chronic Obstructive Pulmonary Disease (COPD) Patients: Towards a Personalized Approach Using Marine Drug Derivatives

Metabolic disorder has been frequently observed in chronic obstructive pulmonary disease (COPD) patients. However, the exact correlation between obesity, which is a complex metabolic disorder, and COPD remains controversial. The current study summarizes a variety of drugs from marine sources that ha...

Full description

Saved in:
Bibliographic Details
Published in:Marine drugs 2017-03, Vol.15 (3), p.81
Main Authors: Lamonaca, Palma, Prinzi, Giulia, Kisialiou, Aliaksei, Cardaci, Vittorio, Fini, Massimo, Russo, Patrizia
Format: Article
Language:English
Subjects:
Adipose tissue
Animals
Aquatic Organisms - chemistry
Bioactive compounds
Biological Factors - chemistry
Biological Factors - pharmacology
Body mass
Body mass index
Chronic obstructive pulmonary disease
comorbidities
Derivatives
Drugs
Humans
Indexing
inflammation
Lung diseases
management strategy
marine compound
Marine microorganisms
Metabolic Diseases - drug therapy
metabolic disorder
Metabolic disorders
Obesity
Obstructive lung disease
Patients
Pulmonary Disease, Chronic Obstructive - drug therapy
Respiratory function
Review
systems approaches
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Metabolic disorder has been frequently observed in chronic obstructive pulmonary disease (COPD) patients. However, the exact correlation between obesity, which is a complex metabolic disorder, and COPD remains controversial. The current study summarizes a variety of drugs from marine sources that have anti-obesity effects and proposed potential mechanisms by which lung function can be modulated with the anti-obesity activity. Considering the similar mechanism, such as inflammation, shared between obesity and COPD, the study suggests that marine derivatives that act on the adipose tissues to reduce inflammation may provide beneficial therapeutic effects in COPD subjects with high body mass index (BMI).
ISSN:1660-3397
1660-3397
DOI:10.3390/md15030081